JP2023540123A5 - - Google Patents

Info

Publication number
JP2023540123A5
JP2023540123A5 JP2023515071A JP2023515071A JP2023540123A5 JP 2023540123 A5 JP2023540123 A5 JP 2023540123A5 JP 2023515071 A JP2023515071 A JP 2023515071A JP 2023515071 A JP2023515071 A JP 2023515071A JP 2023540123 A5 JP2023540123 A5 JP 2023540123A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
polypeptide chain
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023515071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540123A (ja
JP7895931B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/048786 external-priority patent/WO2022051449A2/en
Publication of JP2023540123A publication Critical patent/JP2023540123A/ja
Publication of JP2023540123A5 publication Critical patent/JP2023540123A5/ja
Application granted granted Critical
Publication of JP7895931B2 publication Critical patent/JP7895931B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023515071A 2020-09-04 2021-09-02 P53におけるr273c又はy220cの変異を認識するt細胞受容体 Active JP7895931B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063074747P 2020-09-04 2020-09-04
US63/074,747 2020-09-04
PCT/US2021/048786 WO2022051449A2 (en) 2020-09-04 2021-09-02 T cell receptors recognizing r273c or y220c mutations in p53

Publications (3)

Publication Number Publication Date
JP2023540123A JP2023540123A (ja) 2023-09-21
JP2023540123A5 true JP2023540123A5 (cg-RX-API-DMAC7.html) 2024-09-06
JP7895931B2 JP7895931B2 (ja) 2026-07-28

Family

ID=77924530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515071A Active JP7895931B2 (ja) 2020-09-04 2021-09-02 P53におけるr273c又はy220cの変異を認識するt細胞受容体

Country Status (10)

Country Link
US (1) US20230321240A1 (cg-RX-API-DMAC7.html)
EP (1) EP4208473A2 (cg-RX-API-DMAC7.html)
JP (1) JP7895931B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230066023A (cg-RX-API-DMAC7.html)
CN (1) CN116472050A (cg-RX-API-DMAC7.html)
AU (1) AU2021336399A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191186A1 (cg-RX-API-DMAC7.html)
GB (1) GB2614166A (cg-RX-API-DMAC7.html)
TW (1) TWI900647B (cg-RX-API-DMAC7.html)
WO (1) WO2022051449A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024241888A1 (en) * 2023-03-27 2025-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
WO2026138950A1 (zh) * 2024-12-26 2026-07-02 长春金赛药业有限责任公司 小分子重激活剂化合物在制备治疗抗肿瘤药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
WO2018102585A1 (en) * 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
IL273515B2 (en) * 2017-09-29 2026-03-01 Us Health T cell receptors that recognize mutated P53
JP7391015B2 (ja) * 2017-09-29 2023-12-04 アメリカ合衆国 P53がん特異的変異に対して抗原特異性を有するt細胞を単離する方法

Similar Documents

Publication Publication Date Title
JP2022538148A5 (cg-RX-API-DMAC7.html)
KR20230079259A (ko) Kras 돌연변이 특이적 t세포 수용체의 스크리닝 및 항종양 용도
Ljunggren et al. Empty MHC class I molecules come out in the cold
JP2021505136A5 (cg-RX-API-DMAC7.html)
CN112110995A (zh) 肿瘤新抗原多肽及其用途
JP2020534828A5 (cg-RX-API-DMAC7.html)
JPH08109199A (ja) T細胞抗原受容体に対する抗体
Carbone et al. T cell receptor α-chain pairing determines the specificity of residue 262 within the Kb-restricted, ovalbumin257–264 determinant
GB2609760A (en) HLA Class I-restricted T cell receptors against RAS with G12D mutation
JP2022523024A5 (cg-RX-API-DMAC7.html)
GB2610069A (en) HLA class II-restricted T cell receptors against RAS with G12V mutation
JP2024502235A5 (cg-RX-API-DMAC7.html)
CN113621048A (zh) T细胞抗原受体、其多聚体复合物及其制备方法和应用
WO2006058496A1 (fr) Épitope d'antigène mimétique de her-2 et composition qui comprend un tel épitope
JP2023534241A5 (cg-RX-API-DMAC7.html)
EP3380505A1 (en) Peptides derived from achaete-scute homolog 2 (ascl2), complexes comprising such peptides bound to mhc molecules
CN114302962A (zh) 特异性针对来源于ebv抗原的tcr构建体
CN120607607A (zh) 针对含有g12r突变的ras的hla第ii类限制性t细胞受体
BR112021008617A2 (pt) receptores de nkg2d não naturais que não sinalizam diretamente as células às quais eles estão ligados
JP2010500037A (ja) 無差別papcd4t細胞エピトープ
GB2614166A (en) T cell receptors recognizing R273C or Y220C mutations in P53
CN111378039A (zh) 治疗恶性肿瘤的抗体及其应用
JP2023535366A5 (cg-RX-API-DMAC7.html)
US8658177B2 (en) Promiscuous HER-2/Neu CD4 T cell epitopes
JP2024534499A5 (cg-RX-API-DMAC7.html)